Research Highlights Importance of Consistency in GLP-1 Weight Loss Medications
PHILADELPHIA — GLP-1 medications are among the most sought-after weight loss drugs, but recent research indicates that using them consistently might be crucial for their effectiveness.
A study from the University of Pennsylvania suggests that varying usage of GLP-1 drugs could counteract users’ weight loss goals. The team at Penn’s Leung Lab conducted an experiment involving mice over four months, alternating their intake of semaglutide, a key ingredient found in drugs like Ozempic.
“We started with both groups on the semaglutide, took them off, and then put them back on. We repeated this twice,” explained research specialist Anna Son. “What we observed was quite concerning; this group ended up gaining weight, and the weight gain mainly consisted of fat.”
Researchers observed that the drug’s effectiveness declined after interruptions, even when the mice remained consistently on the drug for an additional 62 days post-reintroduction.
There’s been a significant rise in GLP-1 medication usage, with around one in eight adults turning to these drugs for weight loss. Nevertheless, maintaining consistent usage remains a challenge, as over half of the individuals tend to stop the medication within two years, often attempting to restart later.
“Many users who are on GLP-1 medications frequently discontinue and then restart their treatment,” noted Emmanuel Rapp, a graduate student in the Leung Lab. “This indicates that the drug might develop some level of therapeutic resistance, diminishing its effectiveness.”
Medical experts point out that typical weight loss from GLP-1 medications is comprised of about 40 percent muscle and 60 percent fat. Those who frequently start and stop the medication could face similar challenges as those observed in the mice study.
Although the research was conducted on mice, the implications for human patients are concerning, and it raises questions about how intermittent use could affect them. Further studies are needed to explore whether similar patterns are observed with other weight-loss medications, including newer options like those found in Zepbound.
The main takeaway from this research underlines the necessity for consistency.
